A drug that is already in clinical trials against hepatitis C virus can also prevent hepatitis E virus from replicating.

With more than 170 million individuals currently infected, HCV is a global pandemic, effecting approximately 3% of the entire world's population. HCV infection is a growing infectious disease pandemic ...

Hepatitis C virus (HCV) infects an estimated 50 million people worldwide, according to the World Health Organization, and remains a leading cause of cirrhosis and liver cancer. While antiviral drugs ...

Hepatitis C is the leading cause of chronic liver disease and liver cancer in the world and affects an estimated 51 million people globally. Though the viral infection is easily diagnosable and ...

Every year, four or five people with a medical complaint enter an Irish hospital and discover that many years ago they received a blood transfusion and, unfortunately for them, it was infected with ...

Asymptomatic disease and early progression. The progression of HCV infection to cirrhosis is often asymptomatic and clinically silent. In chronic hepatitis, the correlation of biochemical liver ...

Please provide your email address to receive an email when new articles are posted on . Chronic HCV infection was associated with a 1.8-fold increased risk for pancreatic ductal adenocarcinoma.

Given that HCV is a bloodborne virus, any circumstance that promotes continued drug injection—including failure to prevent or diagnose and adequately treat substance use disorders—can result in ...

In previous articles of this series, we’ve discussed several aspects of the hepatitis C virus including the nature of the infection and its distribution both globally and in the United States. Most ...

The introduction of highly effective direct-acting antivirals has transformed the HCV treatment landscape, enabling cure ...